PTC Therapeutics Inc [PTCT] stock prices are up 5.34% to $78.57 at the moment. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The PTCT shares have gain 3.87% over the last week, with a monthly amount glided 3.93%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
PTC Therapeutics Inc [NASDAQ: PTCT] stock has seen the most recent analyst activity on December 01, 2025, when RBC Capital Mkts downgraded its rating to a Sector Perform but kept the price target unchanged to $91 for it. Previously, Wells Fargo started tracking the stock with Overweight rating on October 20, 2025, and set its price target to $73. On June 17, 2025, Truist initiated with a Buy rating and assigned a price target of $80 on the stock. BofA Securities upgraded its rating to a Buy but stick to its price target of $68 on May 09, 2025. Citigroup upgraded its rating to a Neutral but $40 remained the price target by the analyst firm on May 07, 2025. BofA Securities upgraded its rating to Neutral for this stock on March 11, 2025, and upped its price target to $55. In a note dated March 07, 2025, Scotiabank initiated an Sector Perform rating and provided a target price of $55 on this stock.
The stock price of PTC Therapeutics Inc [PTCT] has been fluctuating between $35.95 and $87.50 over the past year. Currently, Wall Street analysts expect the stock to reach $74.83 within the next 12 months. PTC Therapeutics Inc [NASDAQ: PTCT] shares were valued at $78.57 at the most recent close of the market. An investor can expect a potential drop of -4.76% based on the average PTCT price forecast.
Analyzing the PTCT fundamentals
The PTC Therapeutics Inc [NASDAQ:PTCT] reported sales of 1.78B for trailing twelve months, representing a surge of 7.23%. Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at 0.44%, Pretax Profit Margin comes in at 0.42%, and Net Profit Margin reading is 0.42%. To continue investigating profitability, this company’s Return on Assets is posted at 0.28, Equity is -1.83 and Total Capital is 0.44. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-2.63.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 75.66 points at the first support level, and at 72.74 for the second support level. However, for the 1st resistance point, the stock is sitting at 80.40, and for the 2nd resistance point, it is at 82.22.
Ratios To Look Out For
It’s worth pointing out that PTC Therapeutics Inc [NASDAQ:PTCT]’s Current Ratio is 2.32. Also, the Quick Ratio is 2.26, while the Cash Ratio stands at 0.78. Considering the valuation of this stock, the price to sales ratio is 3.55 and price to earnings (TTM) ratio is 9.18.
Transactions by insiders
Recent insider trading involved Pauwels Eric, CHIEF BUSINESS OFFICER, that happened on Dec 17 ’25 when 40290.0 shares were sold. CHIEF BUSINESS OFFICER, Pauwels Eric completed a deal on Dec 18 ’25 to sell 3202.0 shares. Meanwhile, Officer Pauwels Eric bought 20508.0 shares on Dec 19 ’25.
